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Abstract: Elevated blood pressure is an important cardiovascular risk factor. Although targets 
for both diastolic blood pressure (DBP) and systolic blood pressure (SBP) are deﬁ  ned by current 
guidelines, DBP has historically taken precedence in hypertension management. However, there 
is strong evidence that SBP is superior to DBP as a predictor of cardiovascular events. Moreover, 
achieving control of SBP is assuming greater importance amongst an aging population. In spite 
of the growing recognition of the importance of SBP in reducing cardiovascular risk and the 
emphasis by current guidelines on SBP control, a substantial proportion of patients still fail 
to achieve SBP targets, and SBP control is achieved much less frequently than DBP control. 
Thus, new approaches to the management of hypertension are required in order to control SBP 
and minimize cardiovascular risk. Fixed-dose combination (FDC) therapy is an approach that 
offers the advantages of multiple drug administration and a reduction in regimen complexity 
that favors compliance. We have reviewed the latest evidence demonstrating the efﬁ  cacy in 
targeting SBP of the most recent FDC products; combinations of the calcium channel blocker 
(CCB), amlodipine, with angiotensin receptor blockers (ARBs), valsartan or olmesartan. In 
addition, results from studies with new classes of agent are outlined.
Keywords: hypertension, systolic blood pressure, angiotensin receptor blocker, calcium channel 
blocker, combination therapy
Introduction
Numerous studies have shown that elevated blood pressure (BP) is a major risk 
factor for cardiovascular morbidity and mortality. This relationship, which has been 
demonstrated in a range of patient populations and age groups, is strong and continuous 
(Kannel et al 1971; MacMahon et al 1990; Stamler et al 1993; Adler et al 2000; 
Staessen et al 2000; Padwal et al 2001; Lewington et al 2002).
Blood pressure is a continuous variable with a normal distribution in the population 
(Padwal et al 2001; Chobanian et al 2003). Thus, by necessity, any deﬁ  nition of ‘hyper-
tension’ is arbitrary. However, there is a consensus among many of the major guidelines 
for the treatment of hypertension that individuals with a BP   140/90 mmHg should 
be regarded as hypertensive, and that attempts should be made to keep BP below this 
threshold in all individuals (Chobanian et al 2003; Whitworth 2003; National Collabo-
rating Centre for Chronic Conditions 2006; Mancia et al 2007). Systolic and diastolic 
BP targets are generally lower in patients at high cardiovascular risk and in those with 
diabetes or renal disease (Chobanian et al 2003; Whitworth 2003; Mancia et al 2007).
Diastolic BP (DBP) has historically taken precedence over systolic BP (SBP) in the 
treatment of hypertension. This situation has arisen because early epidemiological and Vascular Health and Risk Management 2008:4(6) 1316
Mourad
interventional trials focused primarily on the risks associated 
with DBP (Black 2004), a focus that has inﬂ  uenced subsequent 
clinical practice. However, a number of large, well-validated 
studies have shown that SBP is a better predictor of cardiovas-
cular risk than DBP in most of the subjects allocated to chronic 
antihypertensive therapy in clinical practice. In addition to 
these observations, the increase in life expectancy observed 
over the last few decades in many developed countries means 
that the paradigm has shifted towards SBP (Black 2004).
Elevations in SBP frequently occur without elevations in 
DBP, a condition known as ‘isolated systolic hypertension’ 
(ISH: SBP   140 mmHg, DBP   90 mmHg) (Chobanian 
et al 2003). Arterial stiffness, endothelial dysfunction, 
atherosclerosis, and oxidative stress all contribute to the 
development of ISH, which is the predominant type of hyper-
tension in elderly patients (Thijs et al 2004; Wallace et al 
2007). Since DBP is, by deﬁ  nition, normal in patients with 
ISH, aggressive lowering of DBP may not be an appropriate 
strategy for this patient group. Moreover, until recently, the 
development of new antihypertensive agents has focused 
almost exclusively on mechanisms that lead to decreased 
DBP, and drugs developed as a result of this strategy may 
not provide optimal management of elevated SBP. Drugs that 
have proven to be particularly useful in the treatment of ISH 
are nitrates, calcium channel blockers (CCBs) and agents that 
target the renin-angiotensin system (RAS, ie, angiotensin 
II receptor blockers [ARBs] and angiotensin converting 
enzyme inhibitors [ACEIs]) because these agents improve 
the large artery stiffness and early wave reﬂ  ection that are 
major characteristics of this condition (Franklin 2000).
Importance of systolic 
blood pressure
The importance of SBP as a predictor of cardiovascular 
risk has been demonstrated in a number of studies. This 
can be clearly seen in the classic meta-analysis of data from 
61 prospective observational studies that involved almost 
1,000,000 individuals with no vascular disease at baseline 
carried out (Lewington et al 2002). This analysis calculated 
the effect of a 20 mmHg difference in usual SBP on the risk 
of stroke and ischemic heart disease (IHD). The authors found 
that for individuals between the ages of 40 and 89 years, a usual 
SBP value that was lower by 20 mmHg was associated with 
signiﬁ  cantly lower risk of death from stroke (hazard ratios, 
0.36–0.67) and IHD (0.49–0.67) (Lewington et al 2002).
The importance of SBP as a predictor of outcome has also 
been demonstrated by the Blood Pressure Lowering Treatment 
Trialists’ Collaboration in a study involving data from over 
160,000 patients enrolled in placebo- and active-controlled 
randomized trials of antihypertensive treatment (Turnbull 
2003). This overview showed that the risks of stroke, major 
cardiovascular events, coronary heart disease (CHD), cardio-
vascular mortality, and total mortality were related to differ-
ences between treatments in SBP (Turnbull 2003). Similar 
results were obtained by Staessen et al (2001, 2003) in two 
meta-analyses that examined the relationship between odds 
ratios for cardiovascular outcomes and differences in SBP 
among different antihypertensive agents (Staessen et al 2001, 
2003). The results of both meta-analyses led to the conclu-
sion that differences in cardiovascular outcome can largely 
be attributed to differences in SBP (Figure 1).
The three studies discussed above (Turnbull 2003; 
Staessen et al 2001, 2003) involved analysis of data from 
hypertensive patients with varying degrees of cardiovascular 
risk. However, the importance of SBP as a cardiovascular risk 
factor has also been demonstrated in subgroups of patients at 
particularly high risk, including those with type 2 diabetes. 
For example, in the United Kingdom Prospective Diabetes 
Study, each 10 mmHg reduction in usual SBP was associated 
with a signiﬁ  cant 11% reduction in the risk of myocardial 
infarction (Adler et al 2000).
These data demonstrate the strong association between 
SBP and cardiovascular risk. However, epidemiological data 
and demographic shifts also serve to emphasize the impor-
tance of SBP in the current management of hypertension. 
For example, data from the 2003–2004 National Health and 
Nutrition Examination Survey (NHANES) show that ISH is 
the most common type of hypertension among individuals 
at high cardiovascular risk (those with pre-existing CVD 
or with comorbidities that predispose to CVD) (Wong et al 
2007). Moreover, SBP is known to increase gradually with age 
whereas DBP tends to decrease in elderly individuals (Black 
2004). Isolated systolic hypertension is thus likely to become 
increasingly prevalent since aging of the population is a feature 
of both developed and developing countries (Kalache and 
Keller 2000). Isolated systolic hypertension is associated with a 
high risk of cardiovascular events such as stroke (SHEP 1991; 
Staessen et al 1997; Liu et al 1998; Inoue et al 2007), and the 
incidence of such complications can be signiﬁ  cantly reduced 
by effective antihypertensive treatment (SHEP 1991; Staessen 
et al 1997, 2000; Liu et al 1998; Waeber 2003). Approximately 
281,000 unnecessary cardiovascular events could be prevented, 
with a healthcare system cost saving of  1.26 billion (based 
upon 2002 costing), if the BP of all patients with hypertension 
in ﬁ  ve European countries (France, Germany, Italy, Sweden, 
and the United Kingdom) was reduced to   140/90 mmHg Vascular Health and Risk Management 2008:4(6) 1317
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(Hansson et al 2002). The predominance of ISH in elderly 
hypertensive patients is likely to explain the observation that 
the importance of SBP as a predictor of CHD risk increases 
with age (Kannel et al 1971).
Superior prediction 
of cardiovascular risk with systolic 
blood pressure
Nearly 40 years ago, data from the Framingham Heart Study 
showed that SBP was more closely associated with risk of 
CHD than DBP (Kannel et al 1971). Although DBP was 
shown to be a more useful predictor of risk in hypertensive 
patients under 45 years old, for the majority of hypertensive 
patients, the ability of SBP to predict CHD was not improved 
by addition of DBP data (Kannel et al 1971). The superior 
predictive ability of SBP was more recently conﬁ  rmed by 
the Prospective Studies Collaboration, a meta-analysis of 
61 prospective observational studies that recorded BP and 
cause-speciﬁ  c mortality (Lewington et al 2002). In this 
study, Lewington et al (2002) found that SBP at baseline 
was more informative than DBP as a predictor of stroke 
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Figure 1 Relationship between odds ratios for cardiovascular events and corresponding differences in systolic blood pressure. Reprinted with permission from Staessen JA, Wang JG, 
Thijs L. 2003. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens, 21:1055–76. Copyright © 2003 Lippincott 
Williams & Wilkins. The left-hand panel shows the relationship between odds ratios for cardiovascular events (experimental treatment versus reference treatment) and differences 
between treatments in achieved systolic blood pressure using data from clinical trials of antihypertensive drugs. The meta-regression line, which is shown with its 95% conﬁ  dence interval, 
was weighted for the inverse of the variance of the individual odds ratios. The right-hand panel shows the results of more recent trials superimposed on the meta-regression line.
Abbreviations: AASK, the African American Study of Kidney disease and hypertension;   ABCD/NT,   Appropriate Blood Pressure Control in Diabetes trial – tight versus usual 
blood pressure control in normotensive patients;   ALLHAT,   Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial;   ALLHAT/Aml,   Antihypertensive and Lipid- 
Lowering treatment to prevent Heart Attack Trial – amlodipine versus chlorthalidone;   ALLHAT/Lis,   Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial 
– lisinopril versus chlorthalidone;   ANBP2,   Australian comparative outcome trial of angiotensin-converting enzyme inhibitor- and diuretic-based treatment of hypertension in the 
elderly;  ATMH,  Australian Trial in Mild Hypertension;  CAPPP,  CAptopril Prevention Project;  CONVINCE,  Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints 
Trial;  DIABHYCAR,  the non-insulin-dependent DIAbetes,  HYpertension, microalbuminuria or proteinuria, Cardiovascular events,  and ramipril study;  ELSA,  European Lacidipine Study 
on Atherosclerosis;  EWPHE, trial conducted by the European Working Party on High blood pressure in the Elderly;  HEP,  trial of Hypertension in Elderly Patients in primary care;  HOPE, 
Heart Outcomes Prevention Evaluation study;  HOT/LH,  Hypertension Optimal Treatment trial – 80 versus 90 mmHg as target diastolic pressure;  HOT/MH,  Hypertension Optimal 
Treatment trial – 85 versus 90 mmHg as target diastolic pressure;  IDNT2,  Irbesartan Diabetic Nephropathy Trial in patients with type-2 diabetes mellitus;  INSIGHT,  International Nife-
dipine GITS Study – Intervention as a Goal for Hypertension Treatment;  LIFE/All,  Losartan Intervention For Endpoint reduction in hypertension study – all patients;  LIFE/DM,  Losartan 
Intervention For Endpoint reduction in hypertension study – diabetic subgroup;  MIDAS/NICS/VHAS, combined results of MIDAS, NICS and   VHAS;  MRC1,  Medical Research Council 
trial of treatment of mild hypertension;  MRC2,  Medical Research Council trial of treatment of hypertension in older adults;  NICOLE,  NIsoldipine in Coronary artery disease in 
LEuven;   NORDIL,   NOrdic DILtiazem study;   PART2,   Prevention of Atherosclerosis with Ramipril Trial;   PART2/SCAT,   combined results of PART2 and SCAT;   PATS,   Post-stroke 
Antihypertensive Treatment Study;  PREVENT,  Prospective Randomized Evaluation of the Vascular Effects Norvasc Trial;  PROGRESS/Com,  perindopril PROtection aGainst REcur-
rent Stroke Study – group on combined therapy;  PROGRESS/Per,  perindopril PROtection aGainst REcurrent Stroke Study – group on single-drug treatment;  RENAAL,  Reduction 
of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan; RCT70–80,  combined results of four smaller trials published from 1970 through 1980, including HSCS, OSLO, 
USPHS, and VACS;   SCOPE,   Study on COgnition and Prognosis in the Elderly;   SHEP,   Systolic Hypertension in the Elderly Program;   STONE,   Shanghai Trial of Nifedipine in the 
Elderly;   STOP1,   Swedish Trial in Old Patients with hypertension;   STOP2/ACEIs,   angiotensin-converting enzyme inhibitor arm of STOP2;   STOP2/CCBs,   calcium-channel blocker 
arm of STOP2;  Syst-China,  Systolic hypertension in China trial;  Syst-Eur,  Systolic hypertension in Europe trial;  UKPDS,  UKPDS hypertension in diabetes study;  UKPDS/CA,  UKPDS 
hypertension in Diabetes Study – captopril versus atenolol;  UKPDS/LH,  UKPDS hypertension in diabetes study – low versus high on-treatment blood pressure.Vascular Health and Risk Management 2008:4(6) 1318
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and IHD mortality. Moreover, the study concluded that, 
in middle-aged individuals, prolonged reductions in usual 
SBP of only 2 mmHg would lead to substantial reductions 
in the incidence of death secondary to stroke (7% reduction) 
and IHD or other vascular causes (10%) (Lewington 
et al 2002).
These ﬁ  ndings are supported by those of Stamler et al 
(1993) who found that SBP had a stronger association with 
cardiovascular risk than DBP in middle-aged and elderly 
individuals. At every level of DBP in this population, a higher 
SBP value was associated with greater cardiovascular risk 
and lower life expectancy (Stamler et al 1993). The results 
of one study, however, demonstrated that gender may be an 
important factor in determining the extent to which DBP also 
plays a role in cardiovascular risk in middle-aged patients 
(Benetos et al 2001). In this study, although SBP was strongly 
associated with mortality both in men and women, DBP 
was also an important predictive factor, but only in women 
(Benetos et al 2001).
More recently, Benetos et al (2003) aimed to deter-
mine whether the high cardiovascular mortality rate of 
treated hypertensive patients was due to hypertension or 
to the presence of associated risk factors and/or diseases. 
Using cardiovascular mortality data from treated hyper-
tensive patients (n = 8893) and from untreated age- and 
gender-matched normotensive and hypertensive controls 
(n = 25,880) enrolled in the Investigations Préventives 
et Cliniques cohort, Benetos et al (2003) found that the 
two-fold increase in cardiovascular and coronary mor-
tality that was apparent in treated hypertensive patients 
persisted after adjustment for cardiovascular risk factors. 
Adjustment for SBP was necessary to render the mortality 
rates similar in the two populations. Subsequent inclusion 
of DBP in the model did not modify the between-group 
risk ratio. These results indicate that the increased car-
diovascular mortality in treated hypertensive patients 
is mainly due to uncontrolled SBP levels (Benetos et al 
2003) (Figure 2).
Systolic BP is also superior to DBP as a predictor of 
adverse renal outcomes in patients with diabetic nephropathy. 
Pohl et al (2005) used data from 1590 hypertensive, diabetic 
patients enrolled in the Irbesartan Diabetic Nephropathy Trial 
to determine the effects of treatment allocation (irbesartan, 
amlodipine, or placebo), and baseline and mean follow-up 
SBP and DBP on progressive renal failure and all-cause 
mortality. Pohl et al (2005) found that follow-up achieved 
SBP was the strongest predictor of an adverse renal outcome 
(doubling of serum creatinine or progression to end-stage 
renal disease). Moreover, the risk associated with inadequate 
control of SBP was substantial. Compared with patients who 
achieved SBP values   134 mmHg, those with SBP levels 
  149 mmHg had more than twice the risk of a renal endpoint. 
Also, values of baseline and achieved SBP that were lower 
by 20 mmHg were associated with relative risks of 0.79 and 
0.52, respectively (Table 1). In contrast, there was no relation-
ship between baseline or achieved DBP and progression of 
renal disease (Table 1) (Pohl et al 2005). Lowering of SBP 
was also associated with reduced risk of death. However, 
although the beneﬁ  cial effects of lowering SBP were graded 
and continuous down to a level of 120 mmHg, the association 
with adverse renal outcomes showed evidence of a plateau 
below this level. Moreover, all-cause mortality showed a 
sharp increase at achieved SBP levels  120 mmHg (Pohl et al 
2005). Pohl et al (2005) concluded that a SBP target between 
120 mmHg and 130 mmHg seems ideal in this population.
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Figure 2 Risk ratios for mortality as a result of cardiovascular disease and coronary 
heart disease in patients treated for hypertension compared with gender- and 
age-matched hypertensive and normotensive subjects (Derived from Benetos 
et al 2003).
Benetos et al (2003) used data from 8893 treated hypertensive patients and 25,880 
untreated age- and gender-matched normotensive and hypertensive control patients 
to determine the inﬂ  uence of hypertension on cardiovascular mortality. Cardiovascular 
and coronary mortality were two-fold higher in the treated population. After 
adjustment for systolic blood pressure (SBP) using Cox regression analysis, the 
differences between the treated and untreated populations decreased from 96% to 
14% (cardiovascular mortality, P = 0.05) and from 99% to 16% (coronary heart disease 
mortality, p = 0.08). Subsequent adjustment for diastolic blood pressure (DBP) had 
no further effect on the risk ratios.Vascular Health and Risk Management 2008:4(6) 1319
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It is evident from the data described above that SBP is a 
more useful predictor of cardiovascular and renal events than 
DBP, although DBP should also be taken into consideration 
in younger patients and in women. Achievement of SBP 
targets should thus be given priority in the majority of patients 
receiving antihypertensive therapy.
Achievement of systolic blood 
pressure targets
In spite of the growing recognition that adequate control of 
SBP is fundamental to reducing cardiovascular risk, a sub-
stantial proportion of patients still fail to achieve the target 
levels deﬁ  ned by current guidelines. For example, data from 
NHANES III show that SBP was controlled to   140 mmHg 
in only 34% of hypertensive patients (treated or untreated) 
(Franklin et al 2001). In contrast, 73% of patients achieved 
DBP control (  90 mmHg). More recent NHANES data 
(2003–2004) have shown that hypertensive patients who 
are receiving treatment but who are not at goal tend to 
be   20 mmHg above their SBP target, and   10 mmHg 
above their DBP target (Wong et al 2007). This situation is 
not restricted to the United States. The Evaluation and Inter-
ventions for Systolic Blood Pressure Elevation – Regional 
and Global (EISBERG) project, which analyzed data from 
more than 17,000 patients in seven countries (Canada, 
France, Germany, Italy, Spain, United Kingdom, and the 
United States), found that a substantially higher percentage 
of patients had DBP controlled to levels endorsed by national 
guidelines than SBP (Swales 1999).
Such differences may result, in part at least, from the 
attitude of physicians, who tended to set less rigorous 
targets for SBP than DBP. A similar bias was reported in 
the Hypertension and Diabetes Screening and Awareness 
(HYDRA) study, which analyzed data from 45,125 primary 
care patients in Germany (Steckelings et al 2004). In this 
study, elevated SBP levels were tolerated by doctors in 51% 
of affected patients. In contrast, elevated DBP levels were 
tolerated in only 41% of affected patients.
One might expect the situation to be better in intervention 
trials, where patient motivation and compliance are likely to 
be high, and the protocol is likely to emphasize achievement 
of target BP. However, even under these conditions, control 
of DBP is achieved more frequently than SBP control. 
For example, in the Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial (ALLHAT), 67% 
of patients achieved SBP   140 mmHg, whereas 92% 
achieved DBP   90 mmHg (Cushman et al 2002). Overall 
control (  140/90 mmHg) was recorded in 66% of patients. 
Similar results were reported from the Controlled ONset 
Verapamil INvestigation of Cardiovascular Endpoints 
(CONVINCE) study, in which 69%–71% and 90% of patients 
maintained control of SBP and DBP, respectively (Black et al 
2001). As in ALLHAT, overall control – which occurred 
in 67%–69% of patients – was similar to the proportion of 
patients who achieved control of SBP.
These results from individual studies are conﬁ  rmed by 
those of Mancia and Grassi (2002) who used data from 
10 controlled trials to show that far fewer patients achieve 
the level of SBP control recommended by guidelines than 
achieve the recommended DBP level (Figure 3). Overall, 
DBP   90 mmHg and SBP   140 mmHg were achieved by 
approximately 90% and 50% of treated patients, respectively 
(Mancia and Grassi 2002). Control of SBP and DBP was 
even worse among patients with diabetes. However, although 
the mean achieved DBP level was lower than the target in 
a number of studies involving diabetic patients, in no study 
did the mean achieved SBP level reach its target.
The relatively poor control of SBP identiﬁ  ed in clinical 
trials is also apparent in specialist clinics and primary care 
practice. For example, in a specialist hypertension clinic 
that documented the effects of managing patients using a 
‘goal oriented’ approach, 63% and 86% of patients achieved 
SBP   140 mmHg and DBP   90 mmHg, respectively 
(Singer et al 2002). Achieving the level of BP control that is 
recommended for patients with diabetes proved particularly 
Table 1 Impact of systolic and diastolic blood pressure on risk of 
an adverse renal outcome (doubling of serum creatinine or progres-
sion to end stage renal disease) (Reproduced with permission from 
Pohl MA, Blumenthal S, Cordonnier DJ, et al. 2005. Independent and 
additive impact of blood pressure control and angiotensin II receptor 
blockade on renal outcomes in the irbesartan diabetic nephropa-
thy trial: clinical implications and limitations.   J Am Soc Nephrol, 
16:3027–37. Copyright © 2005 American Society of Nephrology).
  RR 95% CI P value
Baseline
  SBP lower by 20 mmHg 0.79 0.71, 0.88  0.0001
  DBP lower by 20 mmHg 1.02 0.85, 1.22 0.86
Achieved
  SBP lower by 20 mmHg 0.52 0.45, 0.60  0.0001
  DBP lower by 20 mmHg 1.06 0.84, 1.35 0.61
Notes: Relative risks were computed by applying Cox proportional hazards methods 
to data from 1590 hypertensive patients with type 2 diabetes who were randomized to 
one of three antihypertensive treatment regimens (irbesartan 300 mg/day, amlodipine 
10 mg/day, or placebo). Median patient follow-up was 2.6 years.
Abbreviations: CI, conﬁ  dence interval; DBP, diastolic blood pressure; RR, relative 
risk; SBP, systolic blood pressure.Vascular Health and Risk Management 2008:4(6) 1320
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difﬁ  cult. Only 23% of this group achieved the Joint National 
Committee on Detection, Evaluation, and Treatment of 
High Blood Pressure (JNC) VI SBP goal (Joint National 
Committee 1997) for this population of   130 mmHg 
whereas 68% achieved their DBP goal (  85 mmHg) (Singer 
et al 2002). Similar ﬁ  ndings have been reported from primary 
care. For example, in the HYDRA study, 95% of patients 
with uncontrolled hypertension had elevated SBP levels 
(Steckelings et al 2004). In contrast, DBP was elevated in 
only 50% of patients.
The consistent difference in the levels of SBP and DBP 
control achieved in interventional trials, specialist hyperten-
sion clinics, and primary practice suggests that controlling 
SBP is substantially more difﬁ  cult than controlling DBP. 
Achieving overall control of BP in patients with ISH is 
thus particularly challenging. Moreover, SBP must be 
controlled in this population without excessive lowering of 
DBP (  60 mmHg), because this degree of DBP reduction 
has been associated with reduced survival (Protogerou et al 
2007). This point is probably of particular importance in 
speciﬁ  c populations, such as diabetic patients, subjects with 
overt coronary artery disease and elderly hypertensives in 
whom attempted lowering of SBP to target levels of less 
than 130 mmHg is often associated with inordinate lowering 
of DBP that could lead to an excess in coronary ischemic 
events (Messerli et al 2006; Peralt et al 2007 Osher and 
Stern 2008).
Systolic blood pressure 
in hypertension guidelines
Current guideline recommendations represent a paradigm 
shift towards SBP. This change of emphasis has been 
influenced by the increase in human life expectancy 
(Kalache and Keller 2000), by the results of numer-
ous analyses showing that SBP is a better predictor 
of cardiovascular risk than DBP (Kannel et al 1971; 
Stamler et al 1993; Lewington et al 2002; Benetos et al 
2003; Black 2004), and by recognition that poor control 
of SBP is largely responsible for the prevailing low 
rates of BP control (Lloyd-Jones et al 2000; Hyman 
and Pavlik 2001). These factors have led to emphasis 
of the importance of SBP as a cardiovascular risk factor 
in the current treatment guidelines of the JNC VII and 
the World Health Organization/International Society 
of Hypertension (WHO-ISH) (Chobanian et al 2003; 
Whitworth 2003). Indeed, for patients at low-to-medium 
risk, the WHO/ISH guidelines recommend a target for 
SBP only ( 140 mmHg). This approach is justified by 
evidence from the STRAtegies of Treatment in Hyperten-
sion: Evaluation (STRATHE) study which showed that 
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Figure 3  Achievement of blood pressure goals in controlled trials of antihypertensive agents. Reproduced with permission from Mancia G, Grassi G. 2002. Systolic and diastolic 
blood pressure control in antihypertensive drug trials. J Hypertens, 20:1461–4. Copyright © 2002 Lippincott Williams & Wilkins.
Mancia and Grassi (2002) summarized the effects of antihypertensive treatment on systolic and diastolic blood pressure (SBP and DBP, respectively) in clinical trials involving 
patients with essential hypertension. The data show that higher initial blood pressures (B) are associated with larger reductions during treatment (T). Target blood pressure values 
(SBP, 140 mmHg; DBP, 85–90 mmHg), shown as dotted lines on the graphs, were achieved more frequently for DBP than for SBP. See Figure 1 legend for key to trial names.Vascular Health and Risk Management 2008:4(6) 1321
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if SBP goals are achieved, DBP goals are also likely to 
be realized. For example, in the STRATHE study, only 
3.4% of treated patients with stage 2 hypertension who 
achieved a SBP   140 mmHg retained a DBP   90 
mmHg (Waeber and Mourad 2006). In contrast, 16.6% 
of patients who achieved a DBP   90 mmHg retained a 
SBP   140 mmHg (Figure 4).
New approaches in hypertension 
management
Despite the fact that the literature shows that SBP is an 
extremely important target for blood pressure lowering, 
many physicians remain driven by target achievement for 
DBP. Hypertension thus remains poorly controlled. However, 
there have been changes in understanding of the necessary 
treatment algorithm and it is now well recognized that most 
patients will require combination therapy, initiated as ﬁ  rst 
line or at least early, to achieve guideline BP targets (Mancia 
et al 2007). However, there is an inverse relationship between 
regimen complexity and patient adherence (Osterberg 
and Blaschke 2005; Fung et al 2007), and treatment 
regimens that involve administration of multiple drugs have 
consistently been associated with reduced compliance and 
adherence (Payne and Esmonde-White 2000; Fung et al 
2007). The use of ﬁ  xed-dose combinations represents an 
alternative approach to multiple drug therapy that has been 
shown to improve patient adherence (Elliott 2002; Bangalore 
et al 2007). They also offer the possibility to combine agents 
with different pharmacological proﬁ  les to achieve additive 
effects with enhanced tolerability. The approach of using 
ﬁ  xed-dose combinations as ﬁ  rst-line treatment or earlier in 
patients with comorbidities that require rapid blood pressure 
reduction is endorsed by current guidelines (Chobanian et al 
2003; Mancia et al 2007).
A number of ﬁ  xed-dose combination therapies are already 
in clinical use. These include ACEI/CCB (Jamerson et al 
2004; Roca-Cusachs et al 2008), ACEI/diuretic (Mourad 
et al 2007; Patel et al 2007), and ARB/diuretic (Lacoucière 
et al 2005; Ruilope et al 2005; Neutel et al 2006). There are 
also ﬁ  xed-dose combinations involving β-blockers, although 
the ﬁ  nding that β-blockers may be less effective for stroke 
prevention than other antihypertensive agents (Lindholm 
et al 2005) has led to a trend towards guidelines placing 
less prominence on β-blocker-based therapy (National 
Collaborating Centre for Chronic Conditions 2006; Mancia 
et al 2007).
While there is a paucity of comparative data on the 
various combinations, the recent results from the Avoiding 
Cardiovascular Events in Combination Therapy in Patients 
Living with Systolic Hypertension (ACCOMPLISH) trial 
(Jamerson et al 2008) gives an insight into the effectiveness 
of combinations involving CCB relative to those involv-
ing a diuretic. The results demonstrated that ﬁ  xed-dose 
ACEI/CCB combination therapy signiﬁ  cantly reduced the 
risk of morbidity and mortality relative to ACEI/diuretic 
therapy, despite similar BP reductions. It is unclear to 
what extent these ﬁ  ndings are relevant to other ﬁ  xed-dose 
combinations containing diuretic or CCBs; however, it 
would seem to support the use of ﬁ  xed-dose combination 
therapy involving an agent acting on the RAS, and a CCB 
in hypertensive patients at high risk of developing coronary 
ischemic events.
A new strategy that will add to currently available 
treatment options is a ﬁ  xed-dose combination of an ARB 
with the widely used CCB amlodipine. This promising 
new approach to treatment is currently represented by 
olmesartan medoxomil/amlodipine besylate and valsartan/
amlodipine ﬁ  xed-dose combinations. Aliskiren, an oral renin 
inhibitor, represents another approach to the management of 
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hypertension.  Am J Hypertens, 19:985–6. Copyright © 2006 Nature Publishing Group.
Data from the STRAtegies of Treatment in Hypertension: Evaluation (STRATHE) study show 
that patients who achieve a target systolic blood pressure (SBP)   140 mmHg are also likely 
to achieve a diastolic blood pressure   90 mmHg. In contrast, a substantial proportion of 
patients who achieve DBP   90 mmHg fail to achieve adequate control of SBP. As demon-
strated by the ﬁ  gure, this ﬁ  nding is consistent across a range of treatment regimens.Vascular Health and Risk Management 2008:4(6) 1322
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hypertension that has recently become available. Aliskiren 
is available as monotherapy; a ﬁ  xed-dose combination with 
hydrochlorothiazide (HCTZ) is also available in the United 
States.
Given the importance of controlling SBP, it is important 
to consider the impact of any new therapy on this aspect of 
hypertension. Certainly, the studies published to date on the 
efﬁ  cacy of ARB/amlodipine combination therapy suggest 
that this strategy is capable of producing substantial reduc-
tions in SBP. For example, in a randomized, double-blind, 
placebo-controlled, factorial study involving 1940 patients 
with a mean baseline seated BP level of 164/102 mmHg, 
the combination of olmesartan medoxomil (40 mg/day) and 
amlodipine besylate (10 mg/day) was associated with mean 
SBP reductions of 30.1 mmHg after 8 weeks of treatment 
(Chrysant et al 2008) (Table 2, Figure 5).
Reductions in SBP approaching this magnitude have been 
reported in a registration study for valsartan/amlodipine 
combination therapy. The patients in this trial had less severe 
hypertension at baseline (mean seated BP, 156.7/99.1 mmHg) 
(Philipp et al 2007) than those in the olmesartan/amlodipine 
trial (Chrysant et al 2008) and the mean SBP reduction 
observed after 8 weeks of amlodipine (10 mg/day)/valsartan 
(160 mg/day) was 27.8 mmHg (Table 2) (Philipp et al 2007). 
This dose is equivalent to the maximal marketed dose of 
the drug when administered as a ﬁ  xed-dose combination 
in Europe.
The percentage of patients who achieved their target 
BP was reported in each of these ARB/amlodipine 
studies. However, the goal criteria in the olmesartan/
amlodipine medoxomil study reflect current guideline 
recommendations (BP   130/80 mmHg for patients 
with diabetes,  140/90 mmHg for all others [Chrysant 
et al 2008]) and were more stringent than those defined 
in the valsartan/amlodipine study (DBP   90 mmHg or 
  10 mmHg decrease from baseline [target SBP reduc-
tion not defined] [Philipp et al 2007]). This difference 
invalidates comparison of goal rate achievement between 
the two studies.
Table 2 Reductions in systolic and diastolic blood pressure achieved with aliskiren monotherapy and with amlodipine/valsartan, 
amlodipine/olmesartan, and aliskiren/hydrochlorothiazide combination therapy regimens
Daily treatment 
regimen
Seated DBP 
inclusion criteria 
(mmHg)
n Mean age 
(years)
Mean seated 
BP at baseline 
(mmHg)
Duration of 
treatment 
(weeks)
Mean reduction 
from baseline 
in seated BP 
(mmHg)
Reference
SBP DBP
Amlodipine (10 mg)/
valsartan (160 mg)
 95 and  110 209 56.7 157.4/99.3 8 27.8a 17.6a Philipp et al 
2007
Amlodipine (5–10 mg)/
valsartan (160 mg)
 110 and  120 64 56.5 170.8/112.2 6 35.8 28.6 Poldermans 
et al 2007
Amlodipine (10 mg)/
olmesartan (40 mg)
95–120 162 54.1 165.7/102.4 8 30.1 19.0 Chrysant 
et al 2008
Aliskiren (150→300 mg)b 95–109 560 NR NR 12 17.4 12.2 Schmieder 
et al 2007
Aliskiren (300 mg)/
HCTZ (25 mg)
95–109 173 54.8 154.6/99.3 8 21.2a 14.3a Villamil et al 
2007
aleast squares mean; bforced titration after 3 weeks.
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; NR, data not reported; SBP, systolic blood pressure.
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In the COACH study (Combination of Olmesartan medoxomil and Amlodipine 
besylate in Controlling High blood pressure), patients with a seated diastolic blood 
pressure of 95–120 mmHg at baseline were randomized to receive daily treatment 
with placebo, olmesartan/amlodipine 20/5 mg, 40/5 mg, or 40/10 mg. The ﬁ  gure 
shows the mean reduction from baseline in seated systolic blood pressure (SBP) 
after 8 weeks of treatment.Vascular Health and Risk Management 2008:4(6) 1323
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Patients with severe hypertension require more substantial 
reductions in SBP. However, as demonstrated by Mancia and 
Grassi (2002) in a summary of data from 10 major clinical 
trials, higher initial BPs are typically associated with larger 
reductions during antihypertensive treatment (Figure 3). This 
concept is borne out by the results of a relatively small, recent 
trial involving patients with a mean baseline BP of approxi-
mately 171/112 mmHg (Poldermans et al 2007). Patients 
were treated for 6 weeks with amlodipine (5–10 mg/day)/
valsartan (160 mg/day) or lisinopril (10–20 mg/day)/HCTZ 
(12.5 mg/day). The mean SBP reduction with the amlodipine 
regimen (n = 64) was –35.8 mmHg and with the lisinopril 
regimen (n = 66) it was –31.8 mmHg. The proportion of 
patients achieving SBP goal rates were not reported, but the 
DBP goal of   90 mmHg was achieved by 79.7 and 77.3% 
in the amlodipine and lisinopril groups, respectively.
The results of these recent clinical trials involving ARB/
CCB combination therapy suggest that this therapeutic strat-
egy offers potent lowering of BP and, in particular, substantial 
decreases in SBP. Given the strong association between SBP 
and cardiovascular risk, the advent of ARB/CCB combina-
tions in convenient ﬁ  xed-dose formulations provides a useful 
tool in the management of hypertension, and the consequent 
reduction of cardiovascular morbidity and mortality.
The SBP and DBP reductions achieved with aliskiren, the 
ﬁ  rst-in-class renin inhibitor, are rather more moderate than 
those achieved with the ARB/CCB combinations. A recent 
review of clinical trials involving this agent showed that, 
in studies of patients with DBP   95 and   110 mmHg, 
aliskiren 150–300 mg as monotherapy or in combination with 
other antihypertensive agents produced reductions in SBP of 
between 8.7 and 21.2 mmHg, with approximately one third 
of these values falling between 14 mmHg and 16 mmHg 
(Frampton and Curran 2007). Table 2 shows data from the 
aliskiren monotherapy and combination therapy trials that 
demonstrated the largest reductions in SBP.
One approach that may allow targeted control of SBP 
in the future is the use of advanced glycation endproduct 
(AGE)-crosslink breakers. Advanced glycation endprod-
ucts are believed to contribute to arterial stiffening and 
endothelial dysfunction, both of which increase with 
age. In a recent study, Zieman et al (2007) showed that 
administration of the AGE-crosslink breaker, alagebrium, 
to patients with ISH was associated with improvements in 
endothelial function, and that this correlated with reduc-
tions in vascular ﬁ  brosis. The authors hypothesized that by 
reducing central arterial stiffness and vascular remodeling, 
these ‘destiffening’ agents may lower cardiovascular risk 
in older adults (Zieman et al 2007), however more studies 
are required to conﬁ  rm this. Given the relationship between 
arterial stiffness and cognitive impairment (Hanon et al 
2005), such agents may also lead to improvements in cogni-
tive function in elderly patients. Improvements in cognitive 
function/reduced rate of decline in elderly patients have been 
suggested for CCBs and ARBs (Waeber 2003; Hanon et al 
2006 Shlyakhto 2007).
Conclusions
This review has considered the importance of SBP as a 
predictor of cardiovascular outcome. It is evident from the 
data presented that SBP is a better predictor of cardiovascular 
risk than DBP in most of patients treated with BP lowering 
agents, and is therefore an appropriate target for antihyper-
tensive therapy. This view is shared by current American and 
International guidelines on the management of hypertension, 
both of which place more emphasis on control of SBP than 
DBP (Chobanian et al 2003; Whitworth 2003). Fixed-dose 
ARB/CCB combinations offer convenient and potent BP 
reduction, including powerful reduction of SBP. As a result, 
these combination treatments are likely to contribute sub-
stantially to reducing the risk of cardiovascular events in 
hypertensive patients.
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